Why the study?
Recognising that CVD affects men more than women overall risks underplaying the significant challenges relating to the diagnosis and management of CVD in women.
Answers are grounded in this paper and cite their sources.
Highlights the disparities in cardiovascular disease diagnosis, management, and clinical trial representation for women compared to men.
Although cardiovascular disease (CVD) is recognised to be a condition that affects men more than women overall, this risks underplaying the significant challenges relating to the diagnosis and management of CVD in women. Women are adversely affected compared to men in terms of diagnosis, acute management and implementation of secondary prevention, and the evidence base for treating women is lacking, due to the low numbers of women included in trials. Hormonal fluctuations throughout a woman's lifetime can also affect CVD risk. GPNs are ideally placed to consider the challenges of recognising and addressing CVD risk in women and to support them with engaging in reducing their lifetime risk.
No takes yet. Share an insight, caveat, or question.
Beverley Bostock (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: